» Articles » PMID: 24274329

The (CA)n Polymorphism of ERβ Gene is Associated with FtM Transsexualism

Overview
Journal J Sex Med
Date 2013 Nov 27
PMID 24274329
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Transsexualism is a gender identity disorder with a multifactorial etiology. Neurodevelopmental processes and genetic factors seem to be implicated.

Aim: The aim of this study was to investigate the possible influence of the sex hormone-related genes ERβ (estrogen receptor β), AR (androgen receptor), and CYP19A1 (aromatase) in the etiology of female-to-male (FtM) transsexualism.

Methods: In 273 FtMs and 371 control females, we carried out a molecular analysis of three variable regions: the CA repeats in intron 5 of ERβ; the CAG repeats in exon 1 of AR, and the TTTA repeats in intron 4 of CYP19A1.

Main Outcome Measures: We investigated the possible influence of genotype on transsexualism by performing a molecular analysis of the variable regions of genes ERβ, AR, and CYP19A1 in 644 individuals (FtMs and control females).

Results: FtMs differed significantly from control group with respect to the median repeat length polymorphism ERβ (P = 0.002) but not with respect to the length of the other two studied polymorphisms. The repeat numbers in ERβ were significantly higher in FtMs than in control group, and the likelihood of developing transsexualism was higher (odds ratio: 2.001 [1.15-3.46]) in the subjects with the genotype homozygous for long alleles.

Conclusions: There is an association between the ERβ gene and FtM transsexualism. Our data support the finding that ERβ function is directly proportional to the size of the analyzed polymorphism, so a greater number of repeats implies greater transcription activation, possibly by increasing the function of the complex hormone ERβ receptor and thereby encouraging less feminization or a defeminization of the female brain and behavior.

Citing Articles

A brief historic overview of sexual and gender diversity in neuroscience: past, present, and future.

Moreno J, Manca R, Albrechet-Souza L, Nel J, Spantidakis I, Venter Z Front Hum Neurosci. 2024; 18:1414396.

PMID: 39351068 PMC: 11440198. DOI: 10.3389/fnhum.2024.1414396.


Analysis of single nucleotide polymorphisms of the metabotropic glutamate receptors in a transgender population.

Fernandez R, Ramirez K, Lorente-Bermudez R, Gomez-Gil E, Mora M, Guillamon A Front Endocrinol (Lausanne). 2024; 15:1382861.

PMID: 38919484 PMC: 11196815. DOI: 10.3389/fendo.2024.1382861.


CBLL1 is hypomethylated and correlates with cortical thickness in transgender men before gender affirming hormone treatment.

Fernandez R, Zubiaurre-Elorza L, Santisteban A, Ojeda N, Collet S, Kiyar M Sci Rep. 2023; 13(1):21609.

PMID: 38062063 PMC: 10703770. DOI: 10.1038/s41598-023-48782-2.


Safety of gender affirming treatment in assigned female at birth transgender people and association of androgen and estrogen β receptor polymorphisms with clinical outcomes.

Pallotti F, Senofonte G, Conflitti A, Giancotti A, Anzuini A, Delli Paoli E Endocrine. 2023; 81(3):621-630.

PMID: 37326767 DOI: 10.1007/s12020-023-03421-8.


Erectile function and androgen and estrogen beta receptor gene polymorphisms in acromegalic men.

Pallotti F, Costa D, Hirsch M, Mercuri V, Di Chiano S, Paoli E J Endocrinol Invest. 2023; 47(1):141-147.

PMID: 37306894 PMC: 10776471. DOI: 10.1007/s40618-023-02131-2.